Dr. Michael Lazar

Researchers Find that blood samples may help predict prostate cancer spread

Researchers have found a group of circulating tumor cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool. This is the first time these cell types have been shown to be a promising marker for prostate cancer spread. In a study of around 80 samples from men with prostate cancer, scientists at the Barts Cancer Institute at Queen Mary University looked for cells that were gaining the ability to migrate and invade through the body. Samples with more of these cells were more likely to come from patients whose cancer had spread or was more aggressive. This means that, in the future, these [...]

2017-12-13T13:37:21+00:00 November 15th, 2016|

Researchers discover three novel intrinsic subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Findings represent a step toward the implementation of personalized medicine in prostate cancer care. To diagnose and determine treatment for prostate cancer, clinicians consider many factors, including a digital rectal exam, the prostate specific antigen (PSA) level in a patient's blood and prostate tumor biopsy results. Molecular subtyping of tumor cells allows oncologists to individualize care and tailor treatment based on the actual biology of each patient's [...]

2017-12-13T13:37:21+00:00 November 1st, 2016|

New trial results encourage patients to weigh long-term impact of treatment options with their doctors

(Published on ScienceDaily - September 15, 2016) In light of the findings from the Prostate Testing for Cancer and Treatment (ProtecT) trial published in the New England Journal of Medicine, the American Society for Radiation Oncology (ASTRO) would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study. Their paper emphasizes the importance of joint decision making between prostate cancer patients and their physicians when weighing treatment options for early stage disease. Findings from the ProtecT trial can help patients understand the full range of approaches to manage their disease, including the risks and benefits of active monitoring versus early treatment with radiation therapy (RT) [...]

2017-12-13T13:37:22+00:00 September 20th, 2016|

Understanding Prostate Cancer; Know Your Cancer Risk Factors

Prostate cancer is the most common non-skin cancer in America, affecting 1 in 7 men. But who is most at risk of getting prostate cancer and why? There are several major factors that influence risk, and some of them unfortunately cannot be changed. Age: The older you are, the more likely you are to be diagnosed with prostate cancer. Although only 1 in 10,000 men under age 40 will be diagnosed, the rate shoots up to 1 in 38 for ages 40 to 59, and 1 in 14 for ages 60 to 69. In fact, more than 65% of all prostate cancers are diagnosed in men over the age of 65. The average age at diagnosis of prostate cancer in the United States is 69 [...]

2017-12-13T13:37:22+00:00 September 13th, 2016|

How early can prostate cancer be detected?

Screening is testing to find cancer in people before they have symptoms. For some types of cancer, screening can help find cancers at an early stage, when they are likely to be easier to treat. According to the American Cancer Society, prostate cancer can often be found before symptoms arise by testing the amount of prostate-specific antigen (PSA) in a man’s blood. Another way to find prostate cancer is the digital rectal exam (DRE), in which the doctor puts a gloved, lubricated finger into the rectum to feel the prostate gland. If the results of either one of these tests are abnormal, further testing is often done to see if a man has cancer. If prostate cancer is found as a result of screening with [...]

2017-12-13T13:37:22+00:00 August 9th, 2016|

California HIFU is the Right Choice for Prostate Cancer Treatment

For the past five years, Chris Lockheed’s PSA numbers had been going up. Then, last November, a biopsy revealed that he had two tumors on his prostate. Chris, 68, started doing research into what kind of options for treatment were available to him. When a radiation specialist in Rohnert Park told him about Dr. Michael Lazar and the HIFU procedure, he did more homework. He found that Dr. Lazar had done hundreds of these procedures in Puerto Vallarta, and the treatment was given FDA approval last October. “Dr. Lazar explained everything, and he’s done over 300 of the procedures, that’s why I went to him. I felt very confident. I looked at all of the choices and said ‘this is for me’.” In March, Chris, [...]

2017-12-13T13:37:22+00:00 August 2nd, 2016|

Prostate cancer news: Laser ablation becomes viable treatment option

Prostate cancer news: Laser ablation becomes viable treatment option Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation – the precise application of heat via laser to a tumor – is both feasible and safe in men with intermediate risk prostate cancer. The Phase 1 study found no serious adverse effects or changes in urinary or sexual function six months after the procedure. The technique uses magnetic resonance imaging, or MRI, to guide the insertion of a laser fiber into cancerous tumors. When heated, the laser destroys the cancerous tissue. A follow-up study, presented in a poster presentation at the American Urology Association meeting in May, showed the potential to transfer [...]

2017-12-13T13:37:22+00:00 July 14th, 2016|

Obesity and a high-fat diet promote prostate cancer progression

Metabolites from a fatty diet join forces with the cancer-driving gene MYC to reprogram prostate cancer cells to grow faster, finds new study. This discovery solidifies a direct link between obesity and lethal prostate cancer. At the 2016 Annual American Association for Cancer Research (AACR) Conference, Giorgia Zadra, PhD, of the Harvard: Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented results from a study that helped to clarify the relationship between obesity and prostate cancer. The skinny? Fat increases the activity of a critical cancer-driving gene called MYC. Cancer is a greedy disease. Tumors plunder the body's resources - vitamins and nutrients, energy and oxygen, and vital space as tumors grow to ultimately cause lethal damage. Worst of all, cancer steals precious time away [...]

2017-12-13T13:37:22+00:00 July 5th, 2016|

Mayo Clinic: Tips on Prostate cancer prevention

There's no proven prostate cancer prevention strategy. But one way to reduce the risk of prostate cancer is by making healthy choices, such as exercising and eating a healthy diet. Study results often conflict with each other and most studies aren't designed to definitively prove whether something prevents prostate cancer. As a result, no clear ways to prevent prostate cancer have emerged. In general, doctors recommend that men with an average risk of prostate cancer make choices that benefit their overall health if they're interested in prostate cancer prevention. Choose a healthy diet There is some evidence that choosing a healthy diet that's low in fat and full of fruits and vegetables may contribute to a lower risk of prostate cancer, though this hasn't been [...]

2017-12-13T13:37:22+00:00 June 28th, 2016|

Focal Therapy For Prostate Cancer

 Focal therapy, often referred to as a “male lumpectomy,” is a general term for a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its normal tissue As technology has advanced, physicians now have the ability to diagnose patients with prostate cancer earlier which means that often times tumors within the prostate are small and contained to the prostate. Advanced imaging techniques, allow doctors to pinpoint exactly where the tumor within the prostate is located using multi-parametric MRI and UroNav fusion biopsies, enabling them to target only the tumor within the prostate, leaving other tissue unharmed. Focal therapy is being studied all over the world because of the large potential for reducing side effects such as urinary [...]

2017-12-13T13:37:22+00:00 May 3rd, 2016|